Glycomic Therapeutics Market Growth To $424.67 Billion Creates New Opportunities Across The Industry

Glycomic Therapeutics Market Report

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Glycomic Therapeutics Market Forecast: Value Set To Climb From $221.98 Billion To $424.67 Billion

The glycomic therapeutics market has experienced substantial expansion in recent years. Its size is anticipated to grow from $189.51 billion in 2025 to $221.98 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.1%. This historical growth can be attributed to several factors, including advancements in glycobiology research, the development of enzyme therapy, approvals for rare disease drugs, increased academic research funding, and the expansion of biologics manufacturing.

The glycomic therapeutics market size is anticipated to undergo significant growth over the next few years. It is projected to expand to $424.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.6%. This expansion within the forecast period can be linked to the adoption of precision medicine, the discovery of glycan biomarkers, the enlargement of orphan drug pipelines, innovation in synthetic biology, and increased pharmaceutical research investment. Prominent trends for the forecast period include the broadening of glycan-based drug development, a rising focus on immune modulation therapies, the greater utilization of enzyme replacement therapies, escalating research efforts into rare and metabolic diseases, and the advancement of synthetic glycan technologies.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=49213109&type=smp&name=Glycomic%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glycomic Therapeutics Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The increasing incidence of diabetes is anticipated to propel the expansion of the glycomic therapeutics market. Diabetes is a persistent health condition that impairs the body’s capacity to regulate blood sugar (glucose) levels. Within the context of diabetes, alterations in glycans have been observed, which can contribute to insulin resistance and other metabolic irregularities. Specific glycan patterns function as biomarkers for the diagnosis of diabetes, predicting its progression, and monitoring responses to treatment. For instance, in March 2025, according to GOV.UK, a UK-based non-profit government organization, the prevalence of type 2 diabetes recorded by GPs in adults was 7.0% for those aged 17 and over in England at March 2024, which represented an increase from 6.8% at March 2023. Therefore, the rise in the prevalence of diabetes is stimulating the growth of the glycomic therapeutics market.

Glycomic Therapeutics Market Segment Landscape: Which Areas Lead Development?

The glycomic therapeutics market covered in this report is segmented –

1) By Class: Isolated, Synthetic

2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures

3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action

4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

Subsegments:

1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins

2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

Glycomic Therapeutics Market Innovation Trends: What Developments Are Reshaping The Industry?

Companies operating in the glycomic therapeutics market are concentrating on developing innovative solutions, such as glyco-immune checkpoint inhibitors, to overcome tumor immune evasion and enhance treatment efficacy. Glyco-immune checkpoint inhibitors are therapies designed to block immunosuppressive sugar molecules on cancer cells, helping the immune system better recognize and attack tumors. For instance, in June 2023, Palleon Pharmaceuticals Inc., a US-based biopharmaceutical company, announced that the first patient was dosed in the combination therapy cohort of the Phase 1/2 GLIMMER-01 clinical trial, evaluating their lead glyco-immunology candidate E-602 in combination with cemiplimab (Libtayo®) in patients with advanced cancers. This trial studies E-602 both as a monotherapy and combined with cemiplimab to assess safety, pharmacodynamics, and antitumor activity. E-602 is a first-in-class glyco-immune checkpoint inhibitor designed to enzymatically degrade immunosuppressive sialoglycans on tumor and immune cells, aiming to restore antitumor immunity.

Glycomic Therapeutics Market Industry Leaders And Competitive Landscape

Major companies operating in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ludger Ltd, GlycoMar Limited

View The Full Glycomic Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glycomic Therapeutics Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the glycomic therapeutics in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model